昭衍新药：预计2025年净利润同比增加214.0%到371.0%

Core Viewpoint - The company expects a significant increase in net profit attributable to shareholders for 2025, projecting between RMB 233 million and RMB 349 million, which represents a year-on-year increase of approximately 214.0% to 371.0% compared to the previous year [1] Financial Performance - The projected net profit increase is expected to be between RMB 159 million and RMB 275 million compared to the same period last year [1] - The growth in fair value is driven by a combination of rising market prices for biological assets and natural growth appreciation [1]